Sunshine Biopharma Inc. Marketing Expense
Sunshine Biopharma Inc. (SBFM) reported Marketing Expense of $209.34 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:MarketingExpense · last filed 2026-08-13
- Sunshine Biopharma Inc. marketing expense for the quarter ending 2026-06-30 was $209.34K, a 3.81% increase year-over-year.
- Sunshine Biopharma Inc. marketing expense for the quarter ending 2026-03-31 was $250.22K, a 37.19% decline year-over-year.
- Sunshine Biopharma Inc. marketing expense for the quarter ending 2025-12-31 was $308.69K, a 51.94% increase year-over-year.
- Sunshine Biopharma Inc. marketing expense for the quarter ending 2025-09-30 was $235.22K, a 16.81% decline year-over-year.
- Sunshine Biopharma Inc. marketing expense for fiscal 2025 was $1.14M, a 21.66% increase from fiscal 2024.
- Sunshine Biopharma Inc. marketing expense for fiscal 2024 was $940.28K, a 28.06% increase from fiscal 2023.
- Sunshine Biopharma Inc. marketing expense for fiscal 2023 was $734.25K, a 27.01% increase from fiscal 2022.
- Sunshine Biopharma Inc. marketing expense for fiscal 2022 was $578.09K.
| Period end | Marketing Expense 3 month | Marketing Expense 6 month | Marketing Expense 9 month | Marketing Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $209.34K 10-Q · filed 2026-08-13 | $459.56K 10-Q · filed 2026-08-13 | $768.25K derived: sum of 3 quarters · filed 2026-08-13 | $1.00M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $250.22K 10-Q · filed 2026-05-13 | $558.92K derived: sum of 2 quarters · filed 2026-05-13 | $794.13K derived: sum of 3 quarters · filed 2026-05-13 | $995.79K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $308.69K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-03 | $543.91K derived: sum of 2 quarters · filed 2026-04-03 | $745.57K derived: sum of 3 quarters · filed 2026-08-13 | $1.14M 10-K · filed 2026-04-03 |
| 2025-09-30 | $235.22K 10-Q · filed 2025-11-13 | $436.88K derived: sum of 2 quarters · filed 2026-08-13 | $835.24K 10-Q · filed 2025-11-13 | $1.04M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $201.66K 10-Q · filed 2026-08-13 | $600.02K 10-Q · filed 2026-08-13 | $803.18K derived: sum of 3 quarters · filed 2026-08-13 | $1.09M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $398.36K 10-Q · filed 2026-05-13 | $601.52K derived: sum of 2 quarters · filed 2026-05-13 | $884.27K derived: sum of 3 quarters · filed 2026-05-13 | $1.14M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $203.16K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-03 | $485.91K derived: sum of 2 quarters · filed 2026-04-03 | $742.23K derived: sum of 3 quarters · filed 2026-04-03 | $940.28K 10-K · filed 2026-04-03 |
| 2024-09-30 | $282.75K 10-Q · filed 2025-11-13 | $539.07K derived: sum of 2 quarters · filed 2025-11-13 | $737.12K 10-Q · filed 2025-11-13 | $968.38K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $256.32K 10-Q · filed 2025-08-12 | $454.37K 10-Q · filed 2025-08-12 | $685.63K derived: sum of 3 quarters · filed 2025-08-12 | $927.53K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $198.05K 10-Q · filed 2025-05-15 | $429.31K derived: sum of 2 quarters · filed 2025-05-15 | $671.20K derived: sum of 3 quarters · filed 2025-05-15 | $804.38K derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $231.26K derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-01 | $473.16K derived: sum of 2 quarters · filed 2025-04-01 | $606.34K derived: sum of 3 quarters · filed 2025-04-01 | $734.25K 10-K · filed 2025-04-01 |
| 2023-09-30 | $241.90K 10-Q · filed 2024-11-05 | $375.07K derived: sum of 2 quarters · filed 2024-11-05 | $502.99K 10-Q · filed 2024-11-05 | $680.69K derived: sum of 4 quarters · filed 2024-11-05 |
| 2023-06-30 | $133.18K 10-Q/A · filed 2024-08-20 | $261.09K 10-Q/A · filed 2024-08-20 | $438.79K derived: sum of 3 quarters · filed 2024-08-20 | $656.46K derived: sum of 4 quarters · filed 2024-08-20 |
| 2023-03-31 | $127.91K 10-Q · filed 2024-05-20 | $305.61K derived: sum of 2 quarters · filed 2024-05-20 | $523.28K derived: sum of 3 quarters · filed 2024-05-20 | $610.96K derived: sum of 4 quarters · filed 2024-05-20 |
| 2022-12-31 | $177.70K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $395.37K derived: sum of 2 quarters · filed 2024-03-28 | $483.05K derived: sum of 3 quarters · filed 2024-03-28 | $578.09K 10-K · filed 2024-03-28 |
| 2022-09-30 | $217.67K 10-Q · filed 2023-11-13 | $305.35K derived: sum of 2 quarters · filed 2023-11-13 | $400.39K 10-Q · filed 2023-11-13 | |
| 2022-06-30 | $87.68K 10-Q · filed 2023-08-10 | $182.72K 10-Q · filed 2023-08-10 | ||
| 2022-03-31 | $95.04K 10-Q · filed 2023-05-10 | |||
| 2021-12-31 | $0.00 10-K · filed 2023-04-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |